Clinical Oversight Review Board (CORB) Criteria for Prescribing

Trastuzumab-strf (Hercessi), Trastuzumab-dkst (Ogivri), Trastuzumab (Herceptin), trastuzumab-anns (Kanjinti), trastuzumab-qyyp (Trazimera), Trastuzumab-pkrb (Herzuma), trastuzumab-dttb (Ontruzant)

Notes:

• * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Formulary status Trastuzumab-strf (Hercessi) requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer

Non-formulary status trastuzumab-dkst (Ogivri) requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer
- Patient has failed an adequate trial^ of trastuzumab-strf (Hercessi) or patient has an allergy or intolerance* to of trastuzumab-strf (Hercessi)

Non-formulary status trastuzumab (Herceptin), trastuzumab-anns (Kanjinti), trastuzumab-qyyp (Trazimera), trastuzumab-pkrb (Herzuma), trastuzumab-dttb (Ontruzant) require a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer
- Patient has failed an adequate trial[^] of trastuzumab-strf (Hercessi) -ANDtrastuzumab-dkst (Ogivri) or patient has an allergy or intolerance^{*} to trastuzumab-strf (Hercessi) -AND- tastuzumab-dkst (Ogivri)

<u>Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously:</u>

kp.org

Revised: 08/14/25 Effective: 10/16/25 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



Clinical Oversight Review Board (CORB) Criteria for Prescribing

Trastuzumab-strf (Hercessi), Trastuzumab-dkst (Ogivri), Trastuzumab (Herceptin), trastuzumab-anns (Kanjinti), trastuzumab-qyyp (Trazimera), Trastuzumab-pkrb (Herzuma), trastuzumab-dttb (Ontruzant)

Formulary status Trastuzumab-strf (Hercessi) requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer

Non-formulary status trastuzumab-dkst (Ogivri) requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer
- Patient has failed an adequate trial[^] of trastuzumab-strf (Hercessi) or patient has an allergy or intolerance^{*} to of trastuzumab-strf (Hercessi)


Non-formulary status trastuzumab (Herceptin), trastuzumab-anns (Kanjinti), trastuzumab-qyyp (Trazimera), trastuzumab-pkrb (Herzuma), trastuzumab-dttb (Ontruzant) require a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer
- Patient has failed an adequate trial^ of trastuzumab-strf (Hercessi) -ANDtrastuzumab-dkst (Ogivri) or patient has an allergy or intolerance* to trastuzumab-strf (Hercessi) -AND- tastuzumab-dkst (Ogivri)

kp.org

Revised: 08/14/25 Effective: 10/16/25





Clinical Oversight Review Board (CORB) Criteria for Prescribing

Trastuzumab-strf (Hercessi), Trastuzumab-dkst (Ogivri), Trastuzumab (Herceptin), trastuzumab-anns (Kanjinti), trastuzumab-qyyp (Trazimera), Trastuzumab-pkrb (Herzuma), trastuzumab-dttb (Ontruzant)

<u>Criteria for new members entering Kaiser Permanente already taking the</u> medication who have not been reviewed previously:

Formulary status Trastuzumab-strf (Hercessi) requires a clinical review. Appropriateness of therapy will be based on the following criteria:

- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer

Non-formulary status trastuzumab-dkst (Ogivri) requires a clinical review. Appropriateness of therapy will be based on the following criteria:


- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer
- Patient has failed an adequate trial^ of trastuzumab-strf (Hercessi) or patient has an allergy or intolerance* to of trastuzumab-strf (Hercessi)

Non-formulary status trastuzumab (Herceptin), trastuzumab-anns (Kanjinti), trastuzumab-qyyp (Trazimera), trastuzumab-pkrb (Herzuma), trastuzumab-dttb (Ontruzant) require a clinical review. Appropriateness of therapy will be based on the following criteria:

- Prescribed by Oncology/Hematology provider
- Patients have a diagnosis of HER2 positive breast cancer -OR- HER2 positive gastric/GEJ cancer
- Patient has failed an adequate trial^ of trastuzumab-strf (Hercessi) -ANDtrastuzumab-dkst (Ogivri) or patient has an allergy or intolerance* to trastuzumab-strf (Hercessi) -AND- tastuzumab-dkst (Ogivri)

kp.org

Revised: 08/14/25 Effective: 10/16/25





All plans offered and underwritten by